Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Study summary

This was Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedJDQ443 and trametinib

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · KRAS

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 21, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?13 U.S. locations

Locations may change over time.

Who runs it?Novartis Pharmaceuticals

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Novartis Pharmaceuticals
Interventions being studied: Drug: JDQ443; Drug: trametinib; Drug: Ribociclib; Biological: cetuximab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Biomarkers

KRAS→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Dose Escalation: \- Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy. Phase II:
Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy
Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy. All patients:
ECOG performance status of 0 or 1.
Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines.

Reasons someone may not be able to joinExclusion criteria

Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations
Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II.
Active brain metastases, including symptomatic brain metastases or known leptomeningeal disease
Clinically significant cardiac disease or risk factors at screening
Insufficient bone marrow, hepatic or renal function at screening Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Massachusetts General HospitalBoston, Massachusetts
Dana Farber Cancer InstituteBoston, Massachusetts
NYU School of MedicineNew York, New York
Novartis Investigative SiteLeuven
Novartis Investigative SiteBordeaux
Novartis Investigative SiteLyon
Novartis Investigative SiteFreiburg im Breisgau, Baden-Wurttemberg
Novartis Investigative SiteMilan, MI
Novartis Investigative SiteSingapore
Novartis Investigative SiteSeoul, Seoul
Novartis Investigative SiteBarcelona
Novartis Investigative SiteMadrid

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 21, 2026. Always confirm current availability with the study team.

View original record ↗